S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:BPTH

Bio-Path - BPTH Stock Forecast, Price & News

$3.94
-0.16 (-3.90%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.91
$4.09
50-Day Range
$3.43
$4.43
52-Week Range
$2.68
$8.62
Volume
18,313 shs
Average Volume
49,297 shs
Market Capitalization
$28.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Bio-Path MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
128.4% Upside
$9.00 Price Target
Short Interest
Healthy
3.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of Bio-Path in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.89) to ($1.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

707th out of 1,122 stocks

Pharmaceutical Preparations Industry

355th out of 551 stocks

BPTH stock logo

About Bio-Path (NASDAQ:BPTH) Stock

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. StockNews.com assumed coverage on Bio-Path in a research report on Wednesday. They set a "sell" rating on the stock. HC Wainwright lowered their price target on Bio-Path from $12.00 to $9.00 and set a "buy" rating on the stock in a report on Wednesday, May 18th.

Bio-Path Stock Performance

Shares of BPTH Stock traded down $0.03 on Wednesday, reaching $4.10. 23,423 shares of the company's stock traded hands, compared to its average volume of 30,145. Bio-Path has a 12-month low of $2.68 and a 12-month high of $8.62. The company has a market capitalization of $29.36 million, a P/E ratio of -2.55 and a beta of 1.48. The business's 50 day moving average price is $3.88 and its two-hundred day moving average price is $3.58.

Bio-Path (NASDAQ:BPTH - Get Rating) last issued its quarterly earnings results on Tuesday, August 16th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.08. During the same period in the previous year, the company posted ($0.26) EPS. Research analysts predict that Bio-Path will post -1.89 earnings per share for the current year.

Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

BPTH Stock News Headlines

StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH)
See More Headlines
Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

BPTH Company Calendar

Last Earnings
8/16/2022
Today
8/17/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPTH
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+128.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-10,440,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.56 per share

Miscellaneous

Free Float
6,997,000
Market Cap
$28.21 million
Optionable
Not Optionable
Beta
1.48

Key Executives

  • Mr. Peter H. Nielsen MBA (Age 73)
    Co-Founder, Chairman, CEO, Pres, CFO & Treasurer
    Comp: $680.18k
  • Mr. Douglas P. Morris (Age 66)
    Co-Founder, Director of Investor Relations, Sec. & Director
    Comp: $68.47k
  • Mr. Anthony Price
    Sr. VP of Fin., Accounting & Admin.
  • Dr. Ana Tari Ashizawa Ph.D.
    MBA, Sr. VP of Research, Devel. & Clinical Design
  • Dr. Alan MacKenzie Ph.D.
    Consultant
  • Dr. Thomas A. Walker Ph.D.
    Consultant
  • Dr. Jeffery Lancet M.D.
    Consultant
  • Ms. Victoria Lake Rac
    Regulatory Consultant













BPTH Stock - Frequently Asked Questions

Should I buy or sell Bio-Path stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPTH shares.
View BPTH analyst ratings
or view top-rated stocks.

What is Bio-Path's stock price forecast for 2022?

1 equities research analysts have issued 12-month price targets for Bio-Path's shares. Their BPTH share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 128.4% from the stock's current price.
View analysts price targets for BPTH
or view top-rated stocks among Wall Street analysts.

How have BPTH shares performed in 2022?

Bio-Path's stock was trading at $3.77 at the beginning of 2022. Since then, BPTH shares have increased by 4.5% and is now trading at $3.94.
View the best growth stocks for 2022 here
.

When is Bio-Path's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our BPTH earnings forecast
.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) posted its quarterly earnings data on Tuesday, August, 16th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.08. During the same period in the previous year, the firm posted ($0.26) EPS.

When did Bio-Path's stock split?

Bio-Path's stock reverse split on Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

Who are Bio-Path's major shareholders?

Bio-Path's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.25%).
View institutional ownership trends
.

How do I buy shares of Bio-Path?

Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $3.94.

How much money does Bio-Path make?

Bio-Path (NASDAQ:BPTH) has a market capitalization of $28.21 million. The company earns $-10,440,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The official website for the company is www.biopathholdings.com. The company can be reached via phone at (832) 742-1357 or via email at will@sternir.com.

This page (NASDAQ:BPTH) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.